Tocopherols and tocotrienols represent the two subgroups in the vitamin E family of compounds. However, only tocotrienols display potent antiproliferative and apoptotic activity on mammary cancer cells using treatment doses that have no effect on normal mammary epithelial cell growth or viability. Determining the mechanism(s) mediating the anticancer effects of tocotrienols would provide essential information necessary for understanding the potential health benefits of these compounds in reducing the risk of breast cancer in women. Several signaling pathways have been identified that may be involved in mediating the inhibitory effects of tocotrienols.
The specific aims of this proposal are: 1) to determine the role of vehicle fatty acid composition in modulating tocotrienol absorption and tissue distribution in vivo. Although the in vitro anticancer activity of tocotrienols are firmly established, and dietary intake of palm oil, the richest natural source of tocotrienols, inhibits carcinogen-induced mammary tumorigenesis, while palm oil diets stripped of tocotrienols have no protective effect, dietary supplementation of isolated tocotrienols has produced conflicting results in vivo. Since fat-soluble vitamins (tocotrienols) must be first emulsified by bile before absorption in the gut, and bile excretion is dependent upon the fatty acid composition in the diet, consumption of isolated tocotrienols alone is not sufficient to stimulate adequate bile excretion and is associated with the poor absorption of tocotrienols. It is believed that optimizing tocotrienol absorption and tissue distribution will enhance anticancer potency in vivo. 2) To determine the intracellular signaling mechanism(s) mediating the antiproliferative effects of tocotrienols in preneoplastic and neoplastic mammary epithelial cells in vitro. The antiproliferative effects of tocotrienols are associated with decreased signaling in multiple mitogenic pathways. However, the exact site(s) of action where tocotrienols act to inhibitory mitogenic signaling has not been determined; 3) To determine the intracellular signaling mechanism(s) mediating tocotrienol-induced caspase-8 activation and apoptosis in preneoplastic, neoplastic and malignant mammary epithelial cells in vitro. Although caspase-8 activation is associated with death receptor signaling, the exact receptor/ligand signaling mechanism(s) mediating tocotrienol-induced caspase-8 activation has not been determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Academic Research Enhancement Awards (AREA) (R15)
Project #
2R15CA086833-02
Application #
6780495
Study Section
Special Emphasis Panel (ZRG1-F09 (20))
Program Officer
Perloff, Marjorie
Project Start
2000-07-01
Project End
2008-07-31
Budget Start
2004-08-01
Budget End
2008-07-31
Support Year
2
Fiscal Year
2004
Total Cost
$202,500
Indirect Cost
Name
University of Louisiana at Monroe
Department
Type
Schools of Pharmacy
DUNS #
782279541
City
Monroe
State
LA
Country
United States
Zip Code
71209
Sylvester, Paul W; Ayoub, Nehad M (2013) Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy. Anticancer Agents Med Chem 13:1039-47
Sylvester, Paul W; Wali, Vikram B; Bachawal, Sunitha V et al. (2011) Tocotrienol combination therapy results in synergistic anticancer response. Front Biosci (Landmark Ed) 16:3183-95
Shirode, Amit B; Sylvester, Paul W (2011) Mechanisms Mediating the Synergistic Anticancer Effects of Combined ?-Tocotrienol and Celecoxib Treatment. J Bioanal Biomed 3:1-7
Sylvester, Paul W (2011) Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 716:157-68
Sylvester, Paul W; Kaddoumi, Amal; Nazzal, Sami et al. (2010) The value of tocotrienols in the prevention and treatment of cancer. J Am Coll Nutr 29:324S-333S
Shirode, Amit B; Sylvester, Paul W (2010) Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 64:327-32
Bachawal, Sunitha V; Wali, Vikram B; Sylvester, Paul W (2010) Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 30:429-37
Bachawal, Sunitha V; Wali, Vikram B; Sylvester, Paul W (2010) Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10:84
Samant, G V; Wali, V B; Sylvester, P W (2010) Anti-proliferative effects of gamma-tocotrienol on mammary tumour cells are associated with suppression of cell cycle progression. Cell Prolif 43:77-83
Wali, Vikram B; Bachawal, Sunitha V; Sylvester, Paul W (2009) Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids 44:925-34

Showing the most recent 10 out of 25 publications